Continued FDA approval of iptacopan was contingent on 2-year trial data ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insmed (INSM) and Travere Therapeutics (TVTX). According to TipRanks.com, Skor is a 4-star analyst with ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Dan Yoo took a breath before describing what he saw when he stopped into work on a Sunday morning at the Larry C. Hardy ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of ...

MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases.

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, ...

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported fourth-quarter profit of $2.7 million. The San Diego-based company said it had net income of 3 cents per share.